메뉴 건너뛰기
BJU International
Volumn 94, Issue 7, 2004, Pages 964-966
Prostate cancer screening
Author keywords

[No Author keywords available]
Indexed keywords

ANTINEOPLASTIC AGENT; HORMONE; PROSTATE SPECIFIC ANTIGEN;
EID: 9644281516     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.05187.x     Document Type: Note
Times cited : (13)
References (7)
  • 1
    • 0037068646 scopus 로고    scopus 로고
    • Scandinavian Prostatic Cancer Group Study Number 4. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer
    • Holmberg L, Bill-Axelson A, Helgesen F et al. Scandinavian Prostatic Cancer Group Study Number 4. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347: 781-9
    • (2002) N Engl J Med , vol.347 , pp. 781-789
    • Holmberg, L.1    Bill-Axelson, A.2    Helgesen, F.3
  • 2
    • 0033575051 scopus 로고    scopus 로고
    • Cancer surveillance series: Interpreting trends in prostate cancer - Part I. Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates
    • Hankey BF, Feuer EJ, Clegg LX et al. Cancer surveillance series: interpreting trends in prostate cancer - part I. Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999; 91: 1017-24
    • (1999) J Natl Cancer Inst , vol.91 , pp. 1017-1024
    • Hankey, B.F.1    Feuer, E.J.2    Clegg, L.X.3
  • 3
    • 2442715038 scopus 로고    scopus 로고
    • Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter
    • Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-46
    • (2004) N Engl J Med , vol.350 , pp. 2239-2246
    • Thompson, I.M.1    Pauler, D.K.2    Goodman, P.J.3
  • 4
    • 0025849053 scopus 로고
    • Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
    • Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl Med 1991; 324: 1156-61
    • (1991) N Engl Med , vol.324 , pp. 1156-1161
    • Catalona, W.J.1    Smith, D.S.2    Ratliff, T.L.3
  • 5
    • 0038497523 scopus 로고    scopus 로고
    • Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen
    • Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003; 349: 335-42
    • (2003) N Engl J Med , vol.349 , pp. 335-342
    • Punglia, R.S.1    D'Amico, A.V.2    Catalona, W.J.3    Roehl, K.A.4    Kuntz, K.M.5
  • 6
    • 3042727071 scopus 로고    scopus 로고
    • Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy
    • D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351: 125-35
    • (2004) N Engl J Med , vol.351 , pp. 125-135
    • D'Amico, A.V.1    Chen, M.H.2    Roehl, K.A.3    Catalona, W.J.4
  • 7
    • 0036754570 scopus 로고    scopus 로고
    • Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features
    • Krumholtz JS, Carvalhal GF, Ramos CG et al. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology 2002; 60: 469-73
    • (2002) Urology , vol.60 , pp. 469-473
    • Krumholtz, J.S.1    Carvalhal, G.F.2    Ramos, C.G.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.